Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevenar 13 vs Pneumovax in Untreated CLL
NCT01892618Phase 3Completed
- Sponsor
- Karolinska University Hospital
- Start
- Aug 2013
- Primary completion
- Dec 2015
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Immune response to Pneumovax compared to immune response to Prevenar at 1 month. Started Aug 2013; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT01892618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01892618.